FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2623503649> ?p ?o ?g. }

• W2623503649 endingPage "345" @default.
• W2623503649 startingPage "345" @default.
• W2623503649 abstract "Introduction: Diffuse large B-cell lymphoma (DLBCL) patients with relapsed or refractory disease after rituximab-containing therapy have poor outcomes with current salvage regimens. We conducted a phase 1b/2 trial to analyze the safety and efficacy of adding lenalidomide to R-ESHAP regimen (LR-ESHAP). The phase 1b part of the trial has been completed, and lenalidomide 10 mg/day was identified as the maximum tolerated dose (Br J Haematol 2016; 173: 245-52). Here we present the preliminary results of the phase 2 part (ClinicalTrials.gov Identifier: NCT02340936). Methods: Eligible patients must have relapsed or refractory DLBCL after first-line treatment with rituximab combined with an anthracycline-containing regimen. Subjects received 3 cycles of lenalidomide 10 mg given on days 1 to 14 of every 21-day cycle, in combination with R-ESHAP at standard doses. Responding patients received BEAM conditioning followed by autologous stem-cell transplantation (ASCT). The primary end point was overall response rate (ORR) after 3 cycles of therapy. Secondary end points were complete remission (CR) rate, stem-cell mobilization activity, progression-free survival (PFS), overall survival (OS), and toxicity. Results: A total of 46 patients (median age 58 [23-69] years, 56.5% male) were included (January 2012-November 2015). Evaluable population per-protocol consisted of 44 patients. Forty-two serious adverse events were reported during 128 cycles of LR-ESHAP, including 14 episodes of febrile neutropenia (11%), 12 infections (9%), 2 renal disorders, 3 cardiac disorders, 3 thrombosis, and 8 other toxicities, all of them recovered except 1 case of colon adenocarcinoma. There were no treatment-related deaths. Forty out of 44 patients (91%) received the planned 3 cycles of treatment (2 without lenalidomide in the third cycle). ORR to LR-ESHAP was 68% (41% CR). Patients with relapsed disease had significantly better ORR and CR rates (87% and 67%, respectively) than patients in PR after first-line (77% and 31%) or with primary refractory disease (<PR) (37% and 25%) (p = 0.004 and 0.02, respectively). Evaluation of response according to cell of origin (COO) is ongoing. So far, 30 and 21 patients, respectively, have been analyzed according to Hans' algorithm (ORR of 62% and 44% in germinal-center B-cell-like [GCB] [n = 21] and non-GCB [n = 9] groups, respectively, p > 0.1) and gene expression profiling (ORR of 71%, and 75% in GCB [n = 14], and activated B-cell-like [ABC] [n = 4] groups, respectively, p > 0.1). Thirty-nine out of 42 patients (93%) were successfully mobilized after one (n = 32) or 2 (n = 7) mobilization procedures, and 28 (64% of evaluable patients) underwent ASCT according to protocol, one of them after bone-marrow harvest. With a median follow-up of 15 months (11-53), the estimated 2-year PFS and OS were 54% and 52%, respectively. Conclusions: LR-ESHAP is safe, feasible, and associated with high-response rates in rituximab-pretreated relapsed or refractory DLBCL patients. Efficacy analysis according to COO and other biological factors is ongoing. Keywords: diffuse large B-cell lymphoma (DLBCL); lenalidomide; salvage treatment" @default.
• W2623503649 created "2017-06-15" @default.
• W2623503649 creator A5004401859 @default.
• W2623503649 creator A5006963159 @default.
• W2623503649 creator A5010206363 @default.
• W2623503649 creator A5010733763 @default.
• W2623503649 creator A5029161067 @default.
• W2623503649 creator A5031167522 @default.
• W2623503649 creator A5041947496 @default.
• W2623503649 creator A5044340388 @default.
• W2623503649 creator A5044921844 @default.
• W2623503649 creator A5048566051 @default.
• W2623503649 creator A5054098287 @default.
• W2623503649 creator A5061223719 @default.
• W2623503649 creator A5074244429 @default.
• W2623503649 creator A5077786639 @default.
• W2623503649 creator A5083191976 @default.
• W2623503649 date "2017-06-01" @default.
• W2623503649 modified "2023-10-07" @default.
• W2623503649 title "Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from the Spanish group GELTAMO" @default.
• W2623503649 doi "https://doi.org/10.1002/hon.2439_93" @default.
• W2623503649 hasPublicationYear "2017" @default.
• W2623503649 type Work @default.
• W2623503649 sameAs 2623503649 @default.
• W2623503649 citedByCount "0" @default.
• W2623503649 crossrefType "journal-article" @default.
• W2623503649 hasAuthorship W2623503649A5004401859 @default.
• W2623503649 hasAuthorship W2623503649A5006963159 @default.
• W2623503649 hasAuthorship W2623503649A5010206363 @default.
• W2623503649 hasAuthorship W2623503649A5010733763 @default.
• W2623503649 hasAuthorship W2623503649A5029161067 @default.
• W2623503649 hasAuthorship W2623503649A5031167522 @default.
• W2623503649 hasAuthorship W2623503649A5041947496 @default.
• W2623503649 hasAuthorship W2623503649A5044340388 @default.
• W2623503649 hasAuthorship W2623503649A5044921844 @default.
• W2623503649 hasAuthorship W2623503649A5048566051 @default.
• W2623503649 hasAuthorship W2623503649A5054098287 @default.
• W2623503649 hasAuthorship W2623503649A5061223719 @default.
• W2623503649 hasAuthorship W2623503649A5074244429 @default.
• W2623503649 hasAuthorship W2623503649A5077786639 @default.
• W2623503649 hasAuthorship W2623503649A5083191976 @default.
• W2623503649 hasConcept C126322002 @default.
• W2623503649 hasConcept C141071460 @default.
• W2623503649 hasConcept C143998085 @default.
• W2623503649 hasConcept C2776063141 @default.
• W2623503649 hasConcept C2776364478 @default.
• W2623503649 hasConcept C2776694085 @default.
• W2623503649 hasConcept C2777063308 @default.
• W2623503649 hasConcept C2778559949 @default.
• W2623503649 hasConcept C2778850193 @default.
• W2623503649 hasConcept C2779050716 @default.
• W2623503649 hasConcept C2779338263 @default.
• W2623503649 hasConcept C2780653079 @default.
• W2623503649 hasConcept C2781413609 @default.
• W2623503649 hasConcept C2908647359 @default.
• W2623503649 hasConcept C2911091166 @default.
• W2623503649 hasConcept C31760486 @default.
• W2623503649 hasConcept C71924100 @default.
• W2623503649 hasConcept C90924648 @default.
• W2623503649 hasConcept C99454951 @default.
• W2623503649 hasConceptScore W2623503649C126322002 @default.
• W2623503649 hasConceptScore W2623503649C141071460 @default.
• W2623503649 hasConceptScore W2623503649C143998085 @default.
• W2623503649 hasConceptScore W2623503649C2776063141 @default.
• W2623503649 hasConceptScore W2623503649C2776364478 @default.
• W2623503649 hasConceptScore W2623503649C2776694085 @default.
• W2623503649 hasConceptScore W2623503649C2777063308 @default.
• W2623503649 hasConceptScore W2623503649C2778559949 @default.
• W2623503649 hasConceptScore W2623503649C2778850193 @default.
• W2623503649 hasConceptScore W2623503649C2779050716 @default.
• W2623503649 hasConceptScore W2623503649C2779338263 @default.
• W2623503649 hasConceptScore W2623503649C2780653079 @default.
• W2623503649 hasConceptScore W2623503649C2781413609 @default.
• W2623503649 hasConceptScore W2623503649C2908647359 @default.
• W2623503649 hasConceptScore W2623503649C2911091166 @default.
• W2623503649 hasConceptScore W2623503649C31760486 @default.
• W2623503649 hasConceptScore W2623503649C71924100 @default.
• W2623503649 hasConceptScore W2623503649C90924648 @default.
• W2623503649 hasConceptScore W2623503649C99454951 @default.
• W2623503649 hasLocation W26235036491 @default.
• W2623503649 hasOpenAccess W2623503649 @default.
• W2623503649 hasPrimaryLocation W26235036491 @default.
• W2623503649 hasRelatedWork W2013442295 @default.
• W2623503649 hasRelatedWork W2126772526 @default.
• W2623503649 hasRelatedWork W2134646407 @default.
• W2623503649 hasRelatedWork W2149557304 @default.
• W2623503649 hasRelatedWork W2150129319 @default.
• W2623503649 hasRelatedWork W2168450724 @default.
• W2623503649 hasRelatedWork W2399916762 @default.
• W2623503649 hasRelatedWork W2511121889 @default.
• W2623503649 hasRelatedWork W2534388651 @default.
• W2623503649 hasRelatedWork W4212971766 @default.
• W2623503649 hasVolume "35" @default.
• W2623503649 isParatext "false" @default.
• W2623503649 isRetracted "false" @default.
• W2623503649 magId "2623503649" @default.
• W2623503649 workType "article" @default.